glp 1 stocks Which GLP-1 Drug to Watch in 2025 Hims & Hers Health stock

While effective, these treatments require monitoring due to potential side effects, especially in non-diabetic patients.This therapeutic advancement represents a revolution in the management of metabolic diseases and obesity.Despite their efficacy in managing obesity and metabolic disorders, GLP-1 and GIP receptor agonists can cause side effects, which are a common reason for therapy discontinuation

Read more about the new GLP-1 pill that outperformed oral semaglutide in a recent Phase III trial.

Novo Nordisk (the maker

President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatm

Starting a GLP-1 receptor agonist (GLP-1a) like Mounjaro, Ozempic, or Victoza can lead to meaningful improvements in blood sugar, weight, and appetite control

Your provider reviews the full safety profile with you before you begin